PCVX VAX-31 targets dominant pneumococcal market share
PCVX said its VAX-31 aims for dominant market share with broader pneumococcal vaccine coverage. The company expects pivotal phase III data for VAX-31 by October.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.